Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals PLC partnership with Melinta in MEN

Hikma Pharmaceuticals PLC (LON: HIK) (NASDAQ Dubai: HIK)(OTC: HKMPY) (rated Ba1 Moody’s / BB+ S&P, both stable) announced an exclusive license, supply and distribution agreement with Melinta Therapeutics (Melinta), for Melinta’s intravenous and oral formulations of Baxdela™ (delafloxacin) across all its MENA markets. In addition, Hikma has the right of first negotiation for all other products in Melinta’s portfolio and …

Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals PLC launches Mitomycin for Injection

Hikma Pharmaceuticals PLC (LON: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody’s / BB+ S&P, both stable) announced that Hikma Pharmaceuticals USA Inc., formerly known as West-Ward Pharmaceuticals Corp., has launched Mitomycin for Injection, USP, 20mg and 40mg. Hikma’s Mitomycin for Injection, USP is not recommended as single-agent, primary therapy. It has been shown to be useful in the …